# Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

> **NCT02833350** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 578 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** GDC-0853
- **DRUG:** Adalimumab
- **DRUG:** Folic Acid
- **DRUG:** MTX
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02833350
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-09
- **Primary completion:** 2018-07-02
- **Final completion:** 2018-07-02
- **Target enrollment:** 578 (ACTUAL)
- **Last updated:** 2020-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02833350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02833350, "Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02833350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*